SU
Suven Life Sciences Limited
SUVEN.NS · NSE
₹331.90 -6.65% (-₹23.65)
1M +6.76%
Market Cap ₹81.9B
P/E Ratio -
Div. Yield -
ROE 111.54%
Piotroski F-Score Weak
1/9Valuation
0 /100
Expensive P/B 13.84x
P/S 928.69x
PEG N/A
Growth
22 /100
Declining Book val. growth 16.37%
Rev. growth 19.30%
FCF growth N/A
Profitability
0 /100
Weak FCF margin 1,197.19%
Op. margin 4,228.11%
Gross margin 477.96%
Quality
0 /100
Poor Asset turnover 0.01x
ROA 56.46%
ROIC 61.09%
Debt
69 /100
Low Current ratio 17.69x
Int. coverage -566.85x
Debt/Equity 0.03x
Stability
48 /100
Moderate Profitable years 0
EPS volatility 54.74%
Beta 0.80x
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o SUVEN.NS
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Venkateswarlu Jasti
Employees
141
Headquarters
Hyderabad